1. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. Issue 2 (27th December 2013) Authors: Romagnoli, Mathilde; Mineva, Nora D; Polmear, Michael; Conrad, Catharina; Srinivasan, Srimathi; Loussouarn, Delphine; Barillé‐Nion, Sophie; Georgakoudi, Irene; Dagg, Áine; McDermott, Enda W; Duffy, Michael J; McGowan, Patricia M.; Schlomann, Uwe; Parsons, Maddy; Bartsch, Jörg W; Sonenshein, Gail E Journal: EMBO molecular medicine Issue: Volume 6:Issue 2(2014:Feb.) Page Start: 278 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. (1st October 2019) Authors: Duffy, Michael J; Crown, John Journal: Clinical chemistry Issue: Volume 65:Number 10(2019) Page Start: 1228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA. Issue 5 (May 2018) Authors: Duffy, Michael J; McDermott, Enda W; Crown, John Journal: Tumor biology Issue: Volume 40:Issue 5(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cancer Biomarkers: Clinical Aspects and Laboratory Determination. (2022) Editors: Ramanathan, Lakshmi V; Fleisher, Martin; Duffy, Michael J Record Type: Book Extent: 1 online resource (474 pages) View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Circulating tumour DNA as a cancer biomarker. (January 2019) Authors: Duffy, Michael J Journal: Annals of clinical biochemistry Issue: Volume 56:Number 1(2019:Jan.) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?. (September 2014) Authors: Gaule, Patricia B; Crown, John; O'Donovan, Norma; Duffy, Michael J Journal: Expert opinion on therapeutic targets Issue: Volume 18:Number 9(2014:Sep.) Page Start: 999 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Investigation of molecular alterations of AKT‐3 in triple‐negative breast cancer. Issue 5 (12th December 2013) Authors: O'Hurley, Gillian; Daly, Etáin; O'Grady, Anthony; Cummins, Robert; Quinn, Cecily; Flanagan, Louise; Pierce, Aisling; Fan, Yue; Lynn, Miriam A; Rafferty, Máirín; Fitzgerald, Dara; Pontén, Fredrik; Duffy, Michael J; Jirström, Karin; Kay, Elaine W; Gallagher, William M Journal: Histopathology Issue: Volume 64:Issue 5(2014) Page Start: 660 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Personalized treatment for patients with colorectal cancer: role of biomarkers. (March 2015) Authors: Duffy, Michael J Journal: Biomarkers in medicine Issue: Volume 9:Number 4(2015) Page Start: 337 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells. Issue 4 (April 2016) Authors: Caiazza, Francesco; Murray, Alyson; Madden, Stephen F; Synnott, Naoise C; Ryan, Elizabeth J; O'Donovan, Norma; Crown, John; Duffy, Michael J Journal: Endocrine-related cancer Issue: Volume 23:Issue 4(2016) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy. (6th January 2020) Authors: Duffy, Michael J; McDermott, Enda W; Crown, John Journal: Clinical chemistry Issue: Volume 63:Number 4(2017) Page Start: 804 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗